'Post-sarcoidosis' fatigue: a psychoneuroimmunologic approach

Completed

• Conditions: Morbus Besnier Boeck Schaumann; Sarcoidosis; 10001353; 10027665; 10038716

• Registration Number: NL-OMON30778
• Lead Sponsor: Sint Antonius Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2024-06-18

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 75

Inclusion Criteria

· Evidence on the presence of active sarcoidosis is absent, over the last 6 months:
- normal serum parameters (ACE, serum IL-2, calcium)
- röntgenogram/CTscan: normal or >= 2 yr. stable
- lungfuction: normal or >= 2 yr. stable (< 10% change of VC or FEV1, < 15%change of DLco)
· No clinical evidence of disease activity of previously involved organs
· Sarcoidosis is diagnosed based according to the latest ATS/ERS/WASOG statement on sarcoidosis, i.e.: histologic demonstration of noncaseating granulomas in combination with compatible clinical findings and exclusion of other causes of granuloma formation
· Capability of giving informed consent

Exclusion Criteria

· Sarcoidosis presented as Löfgren*s syndrome
· Medication with corticosteroids or other immunosuppressive drugs over the last 6 months
· Antidepressiva
· Psychiatric diseases (major depression, schizophrenia, dementia, anorexia nervosa. bulimia nervosa)
· Sleep apnoea or narcolepsy or restess legs syndrome
· Any diagnosed disease or any significant abnormal and clinically relevant laboratory test that could possibly contribute to fatigue
(Hb, BSE, leukocytes and differentiation, Na, K, Ca, creatine, bicarbonate, AF, ALAT, creatine phosphokinase (CPK), glucose, total protein, protein spectrum, thyroid stimulating hormone (TSH), ferritine en urine)
· Body Mass Index (BMI): >= 45 or BMI<17
· Abuse of alcohol, drugs or other substance

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified